Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SHANNON NEVILLE WESTIN and ROBERT COLEMAN.
SHANNON NEVILLE WESTIN
Connection Strength
5.460
ROBERT COLEMAN
  1. Individualized Medicine in Ovarian Cancer: Are We There Yet? Gynecol Oncol. 2017 02; 144(2):229-231.
    View in: PubMed
    Score: 0.579
  2. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs. 2013 Feb; 31(1):213-29.
    View in: PubMed
    Score: 0.419
  3. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023 01; 168:76-82.
    View in: PubMed
    Score: 0.216
  4. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
    View in: PubMed
    Score: 0.199
  5. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021 04; 161(1):104-112.
    View in: PubMed
    Score: 0.191
  6. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer. Drugs. 2020 Oct; 80(15):1525-1535.
    View in: PubMed
    Score: 0.187
  7. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
    View in: PubMed
    Score: 0.185
  8. PARP inhibition in the ovarian cancer patient: Current approvals and future directions. Pharmacol Ther. 2020 09; 213:107588.
    View in: PubMed
    Score: 0.182
  9. Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review. Int J Gynecol Cancer. 2020 05; 30(5):684-694.
    View in: PubMed
    Score: 0.179
  10. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer. 2020 07 15; 147(2):413-422.
    View in: PubMed
    Score: 0.176
  11. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer. 2020 01; 30(1):89-93.
    View in: PubMed
    Score: 0.176
  12. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clin Cancer Res. 2020 02 01; 26(3):581-587.
    View in: PubMed
    Score: 0.175
  13. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):420-428.
    View in: PubMed
    Score: 0.174
  14. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 2019 May 28; 10(37):3533-3546.
    View in: PubMed
    Score: 0.170
  15. Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies. Int J Gynecol Cancer. 2019 May 22.
    View in: PubMed
    Score: 0.170
  16. Microsatellite instability in endometrial cancer: New purpose for an old test. Cancer. 2019 07 01; 125(13):2154-2163.
    View in: PubMed
    Score: 0.168
  17. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Curr Treat Options Oncol. 2018 11 15; 19(12):1.
    View in: PubMed
    Score: 0.164
  18. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.
    View in: PubMed
    Score: 0.162
  19. Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer. Oncotarget. 2018 Aug 17; 9(64):32321-32330.
    View in: PubMed
    Score: 0.161
  20. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. Future Oncol. 2018 Dec; 14(30):3101-3110.
    View in: PubMed
    Score: 0.161
  21. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol. 2015 Oct; 9(8):1694-703.
    View in: PubMed
    Score: 0.128
  22. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med. 2024 Aug 10.
    View in: PubMed
    Score: 0.061
  23. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer. 2023 09 04; 33(9):1331-1344.
    View in: PubMed
    Score: 0.057
  24. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022 12 01; 40(34):3952-3964.
    View in: PubMed
    Score: 0.052
  25. Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes. Gynecol Oncol. 2022 07; 166(1):50-56.
    View in: PubMed
    Score: 0.052
  26. A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecol Oncol Rep. 2022 Apr; 40:100974.
    View in: PubMed
    Score: 0.052
  27. Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol. 2022 04; 165(1):82-89.
    View in: PubMed
    Score: 0.051
  28. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2021 12; 31(12):1589-1594.
    View in: PubMed
    Score: 0.050
  29. Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Mol Cancer Ther. 2021 12; 20(12):2352-2361.
    View in: PubMed
    Score: 0.050
  30. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71.
    View in: PubMed
    Score: 0.048
  31. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel). 2021 Feb 09; 13(4).
    View in: PubMed
    Score: 0.048
  32. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021 03; 160(3):777-785.
    View in: PubMed
    Score: 0.048
  33. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 01; 31(1):92-97.
    View in: PubMed
    Score: 0.047
  34. Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstet Gynecol Sci. 2020 Jul; 63(4):417-431.
    View in: PubMed
    Score: 0.046
  35. Improving response to progestin treatment of low-grade endometrial cancer. Int J Gynecol Cancer. 2020 11; 30(11):1811-1823.
    View in: PubMed
    Score: 0.045
  36. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502.
    View in: PubMed
    Score: 0.045
  37. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Sci Rep. 2019 11 26; 9(1):17589.
    View in: PubMed
    Score: 0.044
  38. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019 09; 154(3):524-530.
    View in: PubMed
    Score: 0.043
  39. Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 04; 20(4):570-580.
    View in: PubMed
    Score: 0.042
  40. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018 12; 151(3):428-432.
    View in: PubMed
    Score: 0.041
  41. When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer. 2018 10; 28(8):1485-1490.
    View in: PubMed
    Score: 0.041
  42. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554.
    View in: PubMed
    Score: 0.040
  43. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017 10; 147(1):41-46.
    View in: PubMed
    Score: 0.037
  44. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43.
    View in: PubMed
    Score: 0.035
  45. The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. Expert Rev Qual Life Cancer Care. 2016; 1(3):231-238.
    View in: PubMed
    Score: 0.034
  46. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer. 2014 May; 24(4):713-7.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.